Clinical trials: MMN
Schizophrenia
Event-Related Potential (ERP) Biomarkers in Subjects With Schizophrenia and Healthy Volunteer Subjects
This is an observational, non-interventional study that will recruit Healthy Volunteers (HV) and subjects with clinically confirmed Schizophrenia (SZ).
- Trial name
- NCT04025502
- Testing
- Event-Related Potentials (ERP) and Electroencephalogram (EEG) testing with the COGNISION® System
- Where
- 4 sites in United States
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- ERP Biomarker Qualification Consortium
Growth and Development
A Study to Investigate the Impact of a Multiple Micronutrient (MMN) Beverage Powder on Vaccine Response in School Children
This will be a double blind, two-arm, parallel-group, stratified for gender, randomised, controlled study in participants aged 7-10 years (yrs).
- Trial name
- NCT02551627
- Testing
- Test Product, Control
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers
This is a Phase 0, Double-Blind, Randomized, Placebo-Controlled, Crossover Study to assess the changes in ERP Biomarkers in Healthy Volunteers before and after administration of a sub-anesthetic dose of ketamine.
- Trial name
- NCT04928703
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- ERP Biomarker Qualification Consortium
Growth and Development
fMRI Study to Investigate Hemodynamic Changes in Brain Resulting From Supplementation of Bacopa Monnieri Extract and Multiple Micronutrient Supplementation.
The study will aim to compare the effects of a beverage powder fortified with multiple micronutrients and Bacopa monnieri extract (test product) to a non-fortified isocaloric beverage powder (control product) on cognitive…
- Trial name
- NCT02345187
- Testing
- Beverage powder fortified with Bacopa Monnieri Extract and Multiple Micronutrient supplementation, Non-fortified isocaloric beverage powder
- Where
- India
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Schizophrenia
First Time in Human Study With GSK1018921
GSK1018921 is a new drug under development for the treatment of schizophrenia. GSK1018921 differs from other available drugs in its mode of action and it is assumed that it may have an effect in the treatment of so-called…
- Trial name
- NCT00527020
- Testing
- GSK1018921, Nicotine Lozenges
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cognition
Impact of Beverage Powder With Micronutrients and Brahmi Extract on Cognitive Variables in Indian School Children
The aim of the current study is to investigate the beneficial impact of 4 month consumption of a beverage powder fortified with Brahmi (Bacopa monnieri) extract and multiple vitamins and minerals on short term memory as assessed…
- Trial name
- NCT02416245
- Testing
- Beverage powder fortified with micronutrients and Bacopa monnieri extract, Non fortified isocaloric control (without added micronutrients and Bacopa monnieri extract)
- Where
- India
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline